Last updated on December 2018

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD


Brief description of study

The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD or mild to moderate AD.

The study involves 3 parts.

  • Part A in which participants will receive a single dose of LY3002813 or placebo (no drug).
  • Part B in which participants will receive multiple doses of LY3002813 or placebo for 24 weeks.
  • Part C in which participants will receive multiple doses of LY3002813 or placebo for up to 72 weeks.

Drug will be given as an intravenous infusion (injection into a vein). For Parts A, B and C, the study will last approximately 72 weeks, not including screening of approximately 56 days. The study is for research purposes only and is not intended to treat any medical condition.

Clinical Study Identifier: NCT02624778

Contact Investigators or Research Sites near you

Start Over

Mark Brody

Brain Matters Research
Delray Beach, FL United States

Craig Curtis

Compass Research
Orlando, FL United States

David Subich

Compass Research
The Villages, FL United States

Paolo DePetrillo

SNBL Clinical Pharmacology Center Inc
Baltimore, MD United States

Daniel Gruener

St. Louis Clinical Trials, LC
Saint Louis, MO United States

Shawn Searle

PRA Health Sciences
Salt Lake City, UT United States

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Shinjuku-Ku, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Shinjuku-Ku, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Sumida-ku, Japan

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.